Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Por um escritor misterioso
Descrição
![Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor](https://www.mdpi.com/biomolecules/biomolecules-11-01535/article_deploy/html/images/biomolecules-11-01535-g001-550.jpg)
Biomolecules, Free Full-Text
![Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor](https://www.emjreviews.com/wp-content/uploads/2021/07/Table-5-Bath-Ankylosing-Spondylitis-Activity-Index.jpg)
Treat to Target in Spondyloarthritis: Myth or Reality? - European
![Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor](https://pub.mdpi-res.com/ijms/ijms-23-11561/article_deploy/html/images/ijms-23-11561-g001.png?1664529446)
IJMS, Free Full-Text
![Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor](https://www.emjreviews.com/wp-content/uploads/2021/07/Figure-1-Steps-for-all-patients-taking-part-in-physical.jpg)
Axial Spondyloarthritis: Clinical Characteristics, Epidemiology
![Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor](https://www.researchgate.net/publication/347138192/figure/fig1/AS:983778579197953@1611562499578/A-D-Disease-activity-and-quality-of-life-change-before-and-after-adalimumab.png)
A-D) Disease activity and quality of life change before and after
![Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40744-022-00497-y/MediaObjects/40744_2022_497_Fig4_HTML.png)
Long-Term Adherence to Etanercept in Treatment Effectiveness of
![Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor](https://www.researchgate.net/publication/41623578/figure/fig1/AS:202846625636353@1425373812258/Mean-Bath-Ankylosing-Spondylitis-Disease-Activity-Index-BASDAI-scores-of-the-patients.png)
Mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI
![Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor](https://multimedia.elsevier.es/PublicationsMultimediaV1/file//21735743/0000001900000002/v1_202302031212/S2173574323000084/v1_202302031212/en/main.assets/gr2.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9184xd8ym1IgxXJ6I4p31f1upH6Ra9/FExf9t4wRA9EIdwyxQA4qVT5I6a0jw4uY4u8XmU7h6mX3W0UPNCWDHo2+SOfFjUk7Klik3EDkhaB6wcjePV0iT5rMfH+DmxSH68fFAo5MQOfDAj92dygGzW8bQExtm89GAphEoYcgAs5rBqEtW0NyB9f+XJXy/RBw/UoAkvaseHXOo9vGKqfrSpjGR7XoO2M/W2k8falvgVwQ+KoJTMQKTG54GfmbyMvQKkimog2bQRHhoA1ZN/NaqSk=)
Disease control in patients with ankylosing spondylitis in real
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α
de
por adulto (o preço varia de acordo com o tamanho do grupo)
